H.R. 3379 — Introduced in House

I 116th CONGRESS 1st Session H. R. 3379 IN THE HOUSE OF REPRESENTATIVES June 20, 2019Ms. Schakowsky (for herself, Mr. Westerman, Ms. DeLauro, Ms. Craig, Mr. Doggett, Mr. Krishnamoorthi, Mr. Khanna, Mr. Cicilline, Mr. Pocan, Mr. Rush, Mr. Levin of Michigan, Mr. Morelle, Ms. Jayapal, Ms. Tlaib, Ms. Kaptur, Mr. Welch, and Mr. García of Illinois) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years. 1. Short title This Act may be cited as the Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act. 2. Exclusivity period for brand name biological products (a) In general Section 351(k)(7)(A) of the Public Health Service Act (42 U.S.C. 262(k)(7)(A)) is amended by striking 12 years and inserting 5 years. (b) Conforming changes Paragraphs (2)(A) and (3)(A) of section 351(m) of the Public Health Service Act (42 U.S.C. 262(m)) is amended by striking 12 years each place it appears and inserting 5 years. (c) Applicability This Act and the amendments made by this Act apply only with respect to a biological product for which the reference product (as such term is used in section 351 of the Public Health Service Act (42 U.S.C. 262)) is licensed under subsection (a) of such section on or after the date of enactment of this Act.